Drug Profile
Research programme: analgesic transdermal - Takeda
Alternative Names: SPD 491Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Shire plc
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 21 Feb 2008 Discontinued - Preclinical for Pain in USA (Transdermal)
- 20 Feb 2007 Preclinical trials in Pain in USA (Transdermal)